JAK2 and histiocytic sarcoma: Recent research has noted that the JAK2 inhibitor AG490 hindered the JAK2/STAT3 pathway, which in turn inhibited the abnormal proliferation and fibrosis of keloid fibroblasts, suggesting a potential role for this pathway in the development of HS [19].